

PCH Genetics, Genomics, and Metabolism Grand Rounds 2026

Neuropsychology's Role in X-ALD - 3/5/2026

March 5, 2026 – 2:00 PM

Online

Overall Activity Objectives:

- 1 Utilize clinical practice updates on known genetic disorders, including updates from national professional societies.
- 2 Delineate current and emerging state of the art diagnostic technologies and interpretation.
- 3 Employ as appropriate emerging therapeutics for genetic and metabolic disorders.
- 4 Incorporate into practice current research pertinent to the understanding or reinterpretation of genetic disorders.

Session Objectives:

- 1 Participants will be able to describe functional demyelination in children with X-ALD and CCALD
- 2 Participants will be able to define neuropsychology's role in X-ALD monitoring and evaluation
- 3 Participants will be able to discuss the shift in assessment for functional demyelination since implementation of NBS

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Phoenix Children's. The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Derek E Neilson, MD	Activity Director	Nothing to disclose - 10/21/2025
Ashley M Whitaker, PhD	Faculty	Nothing to disclose - 10/16/2025



THE UNIVERSITY OF ARIZONA

College of Medicine

Tucson